Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  11,451 results for ""Antineoplastic Agents, Immunological""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial.

  • Authors : De Jaeghere EA; Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/adverse effects ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/administration & dosage

  • Source: Gynecologic oncology [Gynecol Oncol] 2024 Dec; Vol. 191, pp. 275-286. Date of Electronic Publication: 2024 Nov 07.Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Pembrolizumab in Japanese patients with primary mediastinal large B-cell lymphoma: results from the KEYNOTE-A33 study.

  • Authors : Kato K; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. .; Nakamura S

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/adverse effects ; Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/drug therapy

  • Source: International journal of clinical oncology [Int J Clin Oncol] 2024 Dec; Vol. 29 (12), pp. 1977-1983. Date of Electronic Publication: 2024 Sep 18.Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 9616295 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer.

  • Authors : Zhang X; Department of Pharmacy, Kunming Yan'an Hospital, Yan'an Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.; Yin WJ

Subjects: Uterine Cervical Neoplasms*/Uterine Cervical Neoplasms*/Uterine Cervical Neoplasms*/drug therapy ; Uterine Cervical Neoplasms*/Uterine Cervical Neoplasms*/Uterine Cervical Neoplasms*/mortality ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use

  • Source: Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology [J Obstet Gynaecol] 2024 Dec; Vol. 44 (1), pp. 2390564. Date of Electronic Publisher: Informa Healthcare Country of Publication: England NLM ID: 8309140 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study.

  • Authors : Kakiuchi Y; Department of Respiratory Medicine, Japan Community Health Care Organization Hitoyoshi Medical Center, Hitoyoshi City, Kumamoto, Japan.; Saruwatari K

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/pathology ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/therapy

  • Source: Clinical lung cancer [Clin Lung Cancer] 2024 Dec; Vol. 25 (8), pp. 661-671.e7. Date of Electronic Publication: 2024 Jul 06.Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Outcomes of weight-based vs. fixed dose of Pembrolizumab among patients with non-small cell lung cancer.

  • Authors : Chaitesipaseut L; Pharmacy Quality & Medication Safety, Kaiser Permanente Northern California, Oakland, California, USA.; Shah N

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/pathology ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use

  • Source: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2024 Dec; Vol. 30 (8), pp. 1352-1357. Publisher: SAGE Publications Country of Publication: England NLM ID: 9511372 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Cost-Effectiveness Analysis of Bevacizumab Biosimilars Versus Originator Bevacizumab for Metastatic Colorectal Cancer: A Comparative Study Using Real-World Data.

  • Authors : Lu B; Sunnybrook Health Sciences Centre, Toronto, ON, Canada.; Dvorani E

Subjects: Bevacizumab*/Bevacizumab*/Bevacizumab*/therapeutic use ; Bevacizumab*/Bevacizumab*/Bevacizumab*/economics ; Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/economics

  • Source: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2024 Dec; Vol. 27 (12), pp. 1689-1697. Date of Electronic Publisher: Elsevier Country of Publication: United States NLM ID: 100883818 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Biosimilar monoclonal antibodies for cancer treatment in adults.

  • Authors : Galvao TF; School of Pharmaceutical Sciences, Universidade Estadual de Campinas, Campinas, Brazil.; Livinalli A

Subjects: Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/therapeutic use ; Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/adverse effects ; Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/therapeutic use

  • Source: The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2024 Nov 28; Vol. 11. Cochrane AN: CD013539. Date of Electronic Publication: 2024 Nov 28.Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-493X

Record details

Read More Add to Saved list
×
Academic Journal

Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial.

  • Authors : Mowery YM; Department of Radiation Oncology, UPMC Hillman Cancer Center-University of Pittsburgh, Pittsburgh, PA, USA; Department of Radiation Oncology, Duke University, Durham, NC, USA

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/adverse effects ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/administration & dosage

  • Source: Lancet (London, England) [Lancet] 2024 Nov 23; Vol. 404 (10467), pp. 2053-2064. Date of Electronic Publication: 2024 Nov 12.Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X

Record details

Read More Add to Saved list
×
Academic Journal

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.

Subjects: Antibodies, Monoclonal*/Antibodies, Monoclonal*/Antibodies, Monoclonal*/administration & dosage ; Antibodies, Monoclonal*/Antibodies, Monoclonal*/Antibodies, Monoclonal*/adverse effects ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/administration & dosage

  • Source: The New England journal of medicine [N Engl J Med] 2024 Nov 14; Vol. 391 (19), pp. 1773-1786. Date of Electronic Publication: 2024 Sep 15.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Impaired cyclin D3 protein degradation contributes to trastuzumab resistance in HER2 positive breast cancer.

  • Authors : Wang Z; Department of Medical Oncology, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, Zhejiang, China.; Laboratory of Cancer Biology, Key Lab of Biotherapy in Zhejiang Province, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

Subjects: Trastuzumab*/Trastuzumab*/Trastuzumab*/pharmacology ; Trastuzumab*/Trastuzumab*/Trastuzumab*/therapeutic use ; Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/drug therapy

  • Source: Medical oncology (Northwood, London, England) [Med Oncol] 2024 Nov 02; Vol. 41 (12), pp. 305. Date of Electronic Publication: 2024 Nov 02.Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-131X

Record details

Read More Add to Saved list
×
  • 1-10 of  11,451 results for ""Antineoplastic Agents, Immunological""